KOL Pulse AI· @KolPulseAI · X·· 1 天前评分70
正文 · 原文
"High rate of hematologic toxicity, with ~50% G3+ anemia, neutropenia and thrombocytopenia, and most patients requiring dose reductions⚠️." @PTarantinoMD
#ESMO26 PANKU-Breast01: iza-bren mPFS 8.18 vs 4.01 mo vs chemo (HR 0.41). Investigational.
https://hubs.ly/Q04Cc-hc0 @bmsnews
42 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：KOL Pulse AI · x.com